activity of the novel Fe-cyclam complex against clinical multidrug-resistant bacterial isolates from Brazil.

To evaluate the effect of a new Fe-cyclam complex on pathogenic bacterial species, including multidrug-resistant clinical specimens. The complex [Fe(cyclam)ox]PF (D2) was tested in cytotoxicity and MIC tests. Clinical and reference strains of Gram-negative and Gram-positive bacteria were used. Considering strains, the profile of antimicrobial susceptibility and time-kill kinetics for D2 was performed. An analysis for D2 was also performed. D2 showed broad bacterial activity, mainly against specimens of , , and . Low cytotoxicity in human cells was demonstrated. The tested compound proved to be a promising agent against resistant bacterial infections.